CA2535449A1 - Complexes comprenant un ligand a base d'acide nucleique a facteur de croissance endotheliale vasculaire (vegf) - Google Patents

Complexes comprenant un ligand a base d'acide nucleique a facteur de croissance endotheliale vasculaire (vegf) Download PDF

Info

Publication number: CA2535449A1
Authority: CA; Canada
Prior art keywords: vegf; nucleic acid; complex; acid ligand; ligand
Prior art date: 1996-10-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002535449A

Other languages

English (en)

Inventor

Nebojsa Janjic

Larry Gold

Paul G. Schmidt

Chandra Vargeese

Michael Willis

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Gilead Sciences Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-25

Filing date

1997-10-17

Publication date

1998-05-07

1996-10-25 Priority claimed from US08/739,109 external-priority patent/US5859228A/en

1997-06-06 Priority claimed from US08/870,930 external-priority patent/US6168778B1/en

1997-07-21 Priority claimed from US08/897,351 external-priority patent/US6051698A/en

1997-10-17 Application filed by Individual filed Critical Individual

1997-10-17 Priority claimed from CA002269072A external-priority patent/CA2269072C/fr

1998-05-07 Publication of CA2535449A1 publication Critical patent/CA2535449A1/fr

Status Abandoned legal-status Critical Current

Links

239000003446 ligand Substances 0.000 title claims abstract description 499
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title claims abstract description 436
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title claims abstract 14
150000007523 nucleic acids Chemical class 0.000 title abstract description 435
102000039446 nucleic acids Human genes 0.000 title abstract description 433
108020004707 nucleic acids Proteins 0.000 title abstract description 433
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title description 425
101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
101150030763 Vegfa gene Proteins 0.000 title 1
150000002634 lipophilic molecules Chemical class 0.000 claims abstract description 86
150000002605 large molecules Chemical class 0.000 claims abstract description 66
239000000203 mixture Substances 0.000 claims description 92
229920001223 polyethylene glycol Polymers 0.000 claims description 84
239000002202 Polyethylene glycol Substances 0.000 claims description 82
230000001225 therapeutic effect Effects 0.000 claims description 35
230000004614 tumor growth Effects 0.000 claims description 26
230000033115 angiogenesis Effects 0.000 claims description 23
229920001515 polyalkylene glycol Polymers 0.000 claims description 20
230000002401 inhibitory effect Effects 0.000 claims description 13
201000010099 disease Diseases 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
230000001404 mediated effect Effects 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims 4
ROMPPAWVATWIKR-UHFFFAOYSA-N 4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]butanoic acid Chemical compound O1C(CCCC(=O)O)=NC(C=2C=CC(Cl)=CC=2)=N1 ROMPPAWVATWIKR-UHFFFAOYSA-N 0.000 claims 1
150000002632 lipids Chemical class 0.000 abstract description 121
238000000034 method Methods 0.000 abstract description 111
102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 421
239000002502 liposome Substances 0.000 description 144
206010028980 Neoplasm Diseases 0.000 description 74
230000027455 binding Effects 0.000 description 66
238000009739 binding Methods 0.000 description 64
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
239000000243 solution Substances 0.000 description 53
108091034117 Oligonucleotide Proteins 0.000 description 52
239000003814 drug Substances 0.000 description 50
-1 Polyethylene glycol Chemical class 0.000 description 47
108091032973 (ribonucleotides)n+m Proteins 0.000 description 45
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 45
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 45
210000004027 cell Anatomy 0.000 description 42
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
229940079593 drug Drugs 0.000 description 33
230000000694 effects Effects 0.000 description 33
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 32
150000003904 phospholipids Chemical class 0.000 description 31
125000003729 nucleotide group Chemical group 0.000 description 30
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 29
150000001875 compounds Chemical class 0.000 description 29
238000005481 NMR spectroscopy Methods 0.000 description 28
238000009472 formulation Methods 0.000 description 28
238000012986 modification Methods 0.000 description 27
230000004048 modification Effects 0.000 description 27
208000007766 Kaposi sarcoma Diseases 0.000 description 26
230000015572 biosynthetic process Effects 0.000 description 26
230000003993 interaction Effects 0.000 description 26
238000003786 synthesis reaction Methods 0.000 description 26
238000002474 experimental method Methods 0.000 description 25
230000001976 improved effect Effects 0.000 description 25
235000019439 ethyl acetate Nutrition 0.000 description 24
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 23
238000012384 transportation and delivery Methods 0.000 description 23
239000012528 membrane Substances 0.000 description 22
210000004379 membrane Anatomy 0.000 description 22
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 21
238000001727 in vivo Methods 0.000 description 20
239000002773 nucleotide Substances 0.000 description 20
239000002953 phosphate buffered saline Substances 0.000 description 20
102000004169 proteins and genes Human genes 0.000 description 20
108090000623 proteins and genes Proteins 0.000 description 20
239000000047 product Substances 0.000 description 19
238000011282 treatment Methods 0.000 description 19
230000012010 growth Effects 0.000 description 18
239000007924 injection Substances 0.000 description 18
238000002347 injection Methods 0.000 description 18
238000006467 substitution reaction Methods 0.000 description 18
239000000032 diagnostic agent Substances 0.000 description 17
229940039227 diagnostic agent Drugs 0.000 description 17
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 17
229940124597 therapeutic agent Drugs 0.000 description 17
241000699670 Mus sp. Species 0.000 description 16
230000005764 inhibitory process Effects 0.000 description 16
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
241001465754 Metazoa Species 0.000 description 15
238000003556 assay Methods 0.000 description 15
238000002360 preparation method Methods 0.000 description 15
238000000638 solvent extraction Methods 0.000 description 15
230000008685 targeting Effects 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
239000000232 Lipid Bilayer Substances 0.000 description 14
201000011510 cancer Diseases 0.000 description 14
150000002313 glycerolipids Chemical class 0.000 description 14
239000000523 sample Substances 0.000 description 14
108020004414 DNA Proteins 0.000 description 13
238000011068 loading method Methods 0.000 description 13
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
125000005647 linker group Chemical group 0.000 description 12
238000011580 nude mouse model Methods 0.000 description 12
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
239000002585 base Chemical group 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
235000012000 cholesterol Nutrition 0.000 description 11
238000010348 incorporation Methods 0.000 description 11
239000011541 reaction mixture Substances 0.000 description 11
239000000741 silica gel Substances 0.000 description 11
229910002027 silica gel Inorganic materials 0.000 description 11
238000007920 subcutaneous administration Methods 0.000 description 11
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 10
230000003321 amplification Effects 0.000 description 10
238000004873 anchoring Methods 0.000 description 10
239000000499 gel Substances 0.000 description 10
230000001965 increasing effect Effects 0.000 description 10
238000003199 nucleic acid amplification method Methods 0.000 description 10
239000003921 oil Substances 0.000 description 10
230000009897 systematic effect Effects 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
210000004881 tumor cell Anatomy 0.000 description 10
241000699660 Mus musculus Species 0.000 description 9
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
239000012634 fragment Substances 0.000 description 9
230000006870 function Effects 0.000 description 9
238000011534 incubation Methods 0.000 description 9
239000000463 material Substances 0.000 description 9
230000008569 process Effects 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
239000002253 acid Substances 0.000 description 8
230000008901 benefit Effects 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
210000002889 endothelial cell Anatomy 0.000 description 8
239000003102 growth factor Substances 0.000 description 8
239000007928 intraperitoneal injection Substances 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
239000007787 solid Substances 0.000 description 8
230000003442 weekly effect Effects 0.000 description 8
102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
229910019142 PO4 Chemical group 0.000 description 7
108091008605 VEGF receptors Proteins 0.000 description 7
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 7
210000004204 blood vessel Anatomy 0.000 description 7
239000012267 brine Substances 0.000 description 7
239000000539 dimer Substances 0.000 description 7
238000010494 dissociation reaction Methods 0.000 description 7
230000005593 dissociations Effects 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
208000002780 macular degeneration Diseases 0.000 description 7
239000002777 nucleoside Substances 0.000 description 7
239000010452 phosphate Chemical group 0.000 description 7
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
239000002904 solvent Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
230000008728 vascular permeability Effects 0.000 description 7
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
101150041968 CDC13 gene Proteins 0.000 description 6
206010012689 Diabetic retinopathy Diseases 0.000 description 6
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 6
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 6
150000001985 dialkylglycerols Chemical class 0.000 description 6
JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 6
102000058223 human VEGFA Human genes 0.000 description 6
230000002209 hydrophobic effect Effects 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
239000010410 layer Substances 0.000 description 6
125000003473 lipid group Chemical group 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
150000004713 phosphodiesters Chemical group 0.000 description 6
230000036470 plasma concentration Effects 0.000 description 6
229920002401 polyacrylamide Polymers 0.000 description 6
230000000717 retained effect Effects 0.000 description 6
125000006850 spacer group Chemical group 0.000 description 6
238000003756 stirring Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 5
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 5
241000700198 Cavia Species 0.000 description 5
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
241000714177 Murine leukemia virus Species 0.000 description 5
101710163270 Nuclease Proteins 0.000 description 5
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
230000000259 anti-tumor effect Effects 0.000 description 5
239000002246 antineoplastic agent Substances 0.000 description 5
230000003305 autocrine Effects 0.000 description 5
239000003012 bilayer membrane Substances 0.000 description 5
239000012148 binding buffer Substances 0.000 description 5
239000001045 blue dye Substances 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
229940126208 compound 22 Drugs 0.000 description 5
239000000562 conjugate Substances 0.000 description 5
230000021615 conjugation Effects 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
239000012043 crude product Substances 0.000 description 5
238000001704 evaporation Methods 0.000 description 5
229920000669 heparin Polymers 0.000 description 5
229960002897 heparin Drugs 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
229910001629 magnesium chloride Inorganic materials 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000002245 particle Substances 0.000 description 5
239000008188 pellet Substances 0.000 description 5
239000012071 phase Substances 0.000 description 5
150000008300 phosphoramidites Chemical class 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
239000000725 suspension Substances 0.000 description 5
239000002691 unilamellar liposome Substances 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 4
QWTBDIBOOIAZEF-UHFFFAOYSA-N 3-[chloro-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile Chemical compound CC(C)N(C(C)C)P(Cl)OCCC#N QWTBDIBOOIAZEF-UHFFFAOYSA-N 0.000 description 4
239000002126 C01EB10 - Adenosine Substances 0.000 description 4
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 4
206010011878 Deafness Diseases 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
201000004681 Psoriasis Diseases 0.000 description 4
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
102000006382 Ribonucleases Human genes 0.000 description 4
108010083644 Ribonucleases Proteins 0.000 description 4
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
229960005305 adenosine Drugs 0.000 description 4
230000002491 angiogenic effect Effects 0.000 description 4
239000000074 antisense oligonucleotide Substances 0.000 description 4
238000012230 antisense oligonucleotides Methods 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
238000009826 distribution Methods 0.000 description 4
239000000975 dye Substances 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
229960003699 evans blue Drugs 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
239000013642 negative control Substances 0.000 description 4
238000003752 polymerase chain reaction Methods 0.000 description 4
239000013615 primer Substances 0.000 description 4
150000003212 purines Chemical class 0.000 description 4
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
238000010898 silica gel chromatography Methods 0.000 description 4
238000000527 sonication Methods 0.000 description 4
238000012453 sprague-dawley rat model Methods 0.000 description 4
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
239000003656 tris buffered saline Substances 0.000 description 4
230000007998 vessel formation Effects 0.000 description 4
UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 description 3
108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
102000053602 DNA Human genes 0.000 description 3
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
241000700159 Rattus Species 0.000 description 3
101710137500 T7 RNA polymerase Proteins 0.000 description 3
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000009471 action Effects 0.000 description 3
238000003314 affinity selection Methods 0.000 description 3
239000003513 alkali Substances 0.000 description 3
229940087168 alpha tocopherol Drugs 0.000 description 3
229920001222 biopolymer Polymers 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000001110 calcium chloride Substances 0.000 description 3
229910001628 calcium chloride Inorganic materials 0.000 description 3
235000011148 calcium chloride Nutrition 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 3
201000000159 corneal neovascularization Diseases 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
150000001982 diacylglycerols Chemical class 0.000 description 3
229960005215 dichloroacetic acid Drugs 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
230000009881 electrostatic interaction Effects 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
239000010408 film Substances 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
125000001153 fluoro group Chemical group F* 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
239000012216 imaging agent Substances 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
229910052749 magnesium Inorganic materials 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
125000003835 nucleoside group Chemical group 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
239000013641 positive control Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
150000003230 pyrimidines Chemical group 0.000 description 3
230000004044 response Effects 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000004448 titration Methods 0.000 description 3
229960000984 tocofersolan Drugs 0.000 description 3
239000002076 α-tocopherol Substances 0.000 description 3
235000004835 α-tocopherol Nutrition 0.000 description 3
FGDJUEZBMFELRW-UHFFFAOYSA-N 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCOCCOCCOCCO)C=C1 FGDJUEZBMFELRW-UHFFFAOYSA-N 0.000 description 2
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 2
ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
241000234282 Allium Species 0.000 description 2
235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
206010015866 Extravasation Diseases 0.000 description 2
DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
208000022873 Ocular disease Diseases 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
229910003873 O—P—O Inorganic materials 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
229930182558 Sterol Natural products 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
108010006785 Taq Polymerase Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical class CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000012190 activator Substances 0.000 description 2
125000003342 alkenyl group Chemical group 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
239000011324 bead Substances 0.000 description 2
239000003124 biologic agent Substances 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
239000007975 buffered saline Substances 0.000 description 2
229960001948 caffeine Drugs 0.000 description 2
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
125000003636 chemical group Chemical group 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
229940044683 chemotherapy drug Drugs 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000001010 compromised effect Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
210000004087 cornea Anatomy 0.000 description 2
239000013058 crude material Substances 0.000 description 2
230000001351 cycling effect Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000000151 deposition Methods 0.000 description 2
238000006642 detritylation reaction Methods 0.000 description 2
239000010432 diamond Substances 0.000 description 2
230000029087 digestion Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000002500 effect on skin Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
230000036251 extravasation Effects 0.000 description 2
230000004438 eyesight Effects 0.000 description 2
150000004665 fatty acids Chemical group 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
235000021588 free fatty acids Nutrition 0.000 description 2
230000004927 fusion Effects 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
229940046257 glyceryl phosphate Drugs 0.000 description 2
239000000833 heterodimer Substances 0.000 description 2
IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
230000005660 hydrophilic surface Effects 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
239000005457 ice water Substances 0.000 description 2
230000009851 immunogenic response Effects 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000004807 localization Effects 0.000 description 2
239000008176 lyophilized powder Substances 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
230000011987 methylation Effects 0.000 description 2
238000007069 methylation reaction Methods 0.000 description 2
239000000693 micelle Substances 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
230000002297 mitogenic effect Effects 0.000 description 2
210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
229920001542 oligosaccharide Polymers 0.000 description 2
150000002482 oligosaccharides Chemical class 0.000 description 2
230000035699 permeability Effects 0.000 description 2
238000005731 phosphitylation reaction Methods 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
210000001525 retina Anatomy 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
229930195734 saturated hydrocarbon Natural products 0.000 description 2
238000010008 shearing Methods 0.000 description 2
238000001542 size-exclusion chromatography Methods 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
150000003432 sterols Chemical class 0.000 description 2
235000003702 sterols Nutrition 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
QULKDBMYSOOKMH-UHFFFAOYSA-N sulfo hydrogen carbonate Chemical compound OC(=O)OS(O)(=O)=O QULKDBMYSOOKMH-UHFFFAOYSA-N 0.000 description 2
230000000153 supplemental effect Effects 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 2
UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 2
229960000278 theophylline Drugs 0.000 description 2
239000010409 thin film Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
230000002792 vascular Effects 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
WUFBVICYRRSKJR-UHFFFAOYSA-O (2-amino-2-hydroperoxyethyl)-trimethylazanium Chemical compound C[N+](C)(C)CC(N)OO WUFBVICYRRSKJR-UHFFFAOYSA-O 0.000 description 1
QEHCYTDFERPPPU-KDXMTYKHSA-N (2s)-2,3-dioctadecoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCOC[C@H](CO)OCCCCCCCCCCCCCCCCCC QEHCYTDFERPPPU-KDXMTYKHSA-N 0.000 description 1
KULQACNMKIDJNN-QTVWNMPRSA-N (2s,3s,4r,5r)-1-aminohexane-1,2,3,4,5,6-hexol Chemical class NC(O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO KULQACNMKIDJNN-QTVWNMPRSA-N 0.000 description 1
JCZPMGDSEAFWDY-MBMOQRBOSA-N (2s,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-MBMOQRBOSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
QPHRQMAYYMYWFW-FJGDRVTGSA-N 1-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@]1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 QPHRQMAYYMYWFW-FJGDRVTGSA-N 0.000 description 1
LOSXTWDYAWERDB-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-2,3-dimethoxybenzene Chemical compound COC1=CC=CC(C(Cl)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1OC LOSXTWDYAWERDB-UHFFFAOYSA-N 0.000 description 1
JBWYRBLDOOOJEU-UHFFFAOYSA-N 1-[chloro-(4-methoxyphenyl)-phenylmethyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 JBWYRBLDOOOJEU-UHFFFAOYSA-N 0.000 description 1
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
OVYNGSFVYRPRCG-UHFFFAOYSA-N 2'-O-Methylguanosine Natural products COC1C(O)C(CO)OC1N1C(NC(N)=NC2=O)=C2N=C1 OVYNGSFVYRPRCG-UHFFFAOYSA-N 0.000 description 1
OVYNGSFVYRPRCG-KQYNXXCUSA-N 2'-O-methylguanosine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=C(N)NC2=O)=C2N=C1 OVYNGSFVYRPRCG-KQYNXXCUSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
RGNOTKMIMZMNRX-XVFCMESISA-N 2-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-4-one Chemical compound NC1=NC(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RGNOTKMIMZMNRX-XVFCMESISA-N 0.000 description 1
TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
XYQGBEGDQHPHSA-UHFFFAOYSA-N 20,21-dihydroxynonatriacontan-19-yl carbonochloridate Chemical compound ClC(=O)OC(C(O)C(O)CCCCCCCCCCCCCCCCCC)CCCCCCCCCCCCCCCCCC XYQGBEGDQHPHSA-UHFFFAOYSA-N 0.000 description 1
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
PJWBTAIPBFWVHX-FJGDRVTGSA-N 4-amino-1-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@](F)(O)[C@H](O)[C@@H](CO)O1 PJWBTAIPBFWVHX-FJGDRVTGSA-N 0.000 description 1
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical class BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical class IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
102000006306 Antigen Receptors Human genes 0.000 description 1
108010083359 Antigen Receptors Proteins 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
108020003566 Antisense Oligodeoxyribonucleotides Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
101710125089 Bindin Proteins 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
0 CC(C(*(C(ON)=O)=C)[U](*(C(O*)=O)=C)=*=C)=O Chemical compound CC(C(*(C(ON)=O)=C)[U](*(C(O*)=O)=C)=*=C)=O 0.000 description 1
208000019300 CLIPPERS Diseases 0.000 description 1
235000002568 Capsicum frutescens Nutrition 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000029147 Collagen-vascular disease Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
229940126639 Compound 33 Drugs 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
229910052688 Gadolinium Inorganic materials 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
206010025421 Macule Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
208000034038 Pathologic Neovascularization Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
101000608752 Phytolacca americana Lectin-C Proteins 0.000 description 1
102100035194 Placenta growth factor Human genes 0.000 description 1
229920000153 Povidone-iodine Polymers 0.000 description 1
241001415846 Procellariidae Species 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
108090000184 Selectins Proteins 0.000 description 1
102000003800 Selectins Human genes 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
206010042618 Surgical procedure repeated Diseases 0.000 description 1
241000589500 Thermus aquaticus Species 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
101150026858 VP30 gene Proteins 0.000 description 1
102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
108010059722 Viral Fusion Proteins Proteins 0.000 description 1
VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
XLLNINGEDIOQGQ-UHFFFAOYSA-N [acetyloxy(hydroxy)phosphoryl] acetate Chemical compound CC(=O)OP(O)(=O)OC(C)=O XLLNINGEDIOQGQ-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
210000001643 allantois Anatomy 0.000 description 1
BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
230000006427 angiogenic response Effects 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000001399 anti-metabolic effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000729 antidote Substances 0.000 description 1
229940075522 antidotes Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
239000003293 antisense oligodeoxyribonucleotide Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000012865 aseptic processing Methods 0.000 description 1
CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000004856 capillary permeability Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000007942 carboxylates Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
229940033883 chloramphenicol ophthalmic solution Drugs 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000006854 communication Effects 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125846 compound 25 Drugs 0.000 description 1
229940125851 compound 27 Drugs 0.000 description 1
229940127204 compound 29 Drugs 0.000 description 1
229940125877 compound 31 Drugs 0.000 description 1
238000004590 computer program Methods 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
210000003683 corneal stroma Anatomy 0.000 description 1
239000010779 crude oil Substances 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
230000003413 degradative effect Effects 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000011363 dried mixture Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000002296 dynamic light scattering Methods 0.000 description 1
238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
231100001129 embryonic lethality Toxicity 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
239000002038 ethyl acetate fraction Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
102000036444 extracellular matrix enzymes Human genes 0.000 description 1
108091007167 extracellular matrix enzymes Proteins 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229940014144 folate Drugs 0.000 description 1
102000006815 folate receptor Human genes 0.000 description 1
108020005243 folate receptor Proteins 0.000 description 1
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
230000010005 growth-factor like effect Effects 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
238000013415 human tumor xenograft model Methods 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
150000002433 hydrophilic molecules Chemical class 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
235000013490 limbo Nutrition 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
229920001427 mPEG Polymers 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000034217 membrane fusion Effects 0.000 description 1
INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
229960002409 mepivacaine Drugs 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
XWHKJDYPOHFFPI-UHFFFAOYSA-N n-[2-hydroxy-3-(octadecanoylamino)propyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCC(O)CNC(=O)CCCCCCCCCCCCCCCCC XWHKJDYPOHFFPI-UHFFFAOYSA-N 0.000 description 1
238000011587 new zealand white rabbit Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000012285 osmium tetroxide Substances 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
229920001281 polyalkylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229960001621 povidone-iodine Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000002213 purine nucleotide Substances 0.000 description 1
239000002719 pyrimidine nucleotide Substances 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
239000000941 radioactive substance Substances 0.000 description 1
238000009790 rate-determining step (RDS) Methods 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000010837 receptor-mediated endocytosis Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
229940100618 rectal suppository Drugs 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000006884 regulation of angiogenesis Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
239000012146 running buffer Substances 0.000 description 1
229910052594 sapphire Inorganic materials 0.000 description 1
239000010980 sapphire Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
238000004513 sizing Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
238000002791 soaking Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000010257 thawing Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
ISPSHPOFLYFIRR-UHFFFAOYSA-N trihexylsilicon Chemical compound CCCCCC[Si](CCCCCC)CCCCCC ISPSHPOFLYFIRR-UHFFFAOYSA-N 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000006216 vaginal suppository Substances 0.000 description 1
229940120293 vaginal suppository Drugs 0.000 description 1
230000006711 vascular endothelial growth factor production Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
239000002525 vasculotropin inhibitor Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000004304 visual acuity Effects 0.000 description 1
239000011800 void material Substances 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002535449A 1996-10-25 1997-10-17 Complexes comprenant un ligand a base d'acide nucleique a facteur de croissance endotheliale vasculaire (vegf) Abandoned CA2535449A1 (fr)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US08/739,109 US5859228A (en)	1995-05-04	1996-10-25	Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US08/739,109		1996-10-25
US08/870,930 US6168778B1 (en)	1990-06-11	1997-06-06	Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US08/870,930		1997-06-06
US08/897,351 US6051698A (en)	1997-06-06	1997-07-21	Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US08/897,341		1997-07-21
CA002269072A CA2269072C (fr)	1996-10-25	1997-10-17	Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002269072A Division CA2269072C (fr)	1996-10-25	1997-10-17	Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire

Publications (1)

Publication Number	Publication Date
CA2535449A1 true CA2535449A1 (fr)	1998-05-07

Family

ID=36283173

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002535449A Abandoned CA2535449A1 (fr)	1996-10-25	1997-10-17	Complexes comprenant un ligand a base d'acide nucleique a facteur de croissance endotheliale vasculaire (vegf)

Country Status (1)

Country	Link
CA (1)	CA2535449A1 (fr)

1997
- 1997-10-17 CA CA002535449A patent/CA2535449A1/fr not_active Abandoned

Legal Events

Date	Code	Title	Description
2006-07-11	EEER	Examination request
2012-10-17	FZDE	Dead

Publication	Publication Date	Title
CA2269072C (fr)	2006-02-14	Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire
US6426335B1 (en)	2002-07-30	Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6051698A (en)	2000-04-18	Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6168778B1 (en)	2001-01-02	Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US5859228A (en)	1999-01-12	Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6147204A (en)	2000-11-14	Nucleic acid ligand complexes
US6465188B1 (en)	2002-10-15	Nucleic acid ligand complexes
AU749273B2 (en)	2002-06-20	Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US6011020A (en)	2000-01-04	Nucleic acid ligand complexes
AU728176B2 (en)	2001-01-04	Nucleic acid ligand complexes
US8071737B2 (en)	2011-12-06	Nucleic acid ligand complexes
CA2535449A1 (fr)	1998-05-07	Complexes comprenant un ligand a base d'acide nucleique a facteur de croissance endotheliale vasculaire (vegf)
JP5637528B2 (ja)	2014-12-10	核酸リガンド複合体